AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 286: E786-E794, 2004. First published January 13, 2004; doi:10.1152/ajpendo.00477.2003
0193-1849/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/5/E786    most recent
00477.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suarez, C.
Right arrow Articles by Becu-Villalobos, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suarez, C.
Right arrow Articles by Becu-Villalobos, D.

Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia

Cecilia Suarez, Graciela Díaz-Torga, Arturo González-Iglesias, Carolina Cristina, and Damasia Becu-Villalobos

Instituto de Biología y Medicina Experimental-Consejo Nacional de Investigaciones Científicas y Técnicas, 1428 Buenos Aires, Argentina

Submitted 21 October 2003 ; accepted in final form 5 January 2004

Recent evidence shows that reexpression and upregulation of angiotensin II (ANG II) type 2 (AT2) receptor in adult tissues occur during pathological conditions such as tissue hyperplasia, inflammation, and remodeling. In particular, expression of functional AT2 receptors in the pituitary and their physiological significance and regulation have not been described. In this study, we demonstrate that chronic in vivo estrogen treatment, which induces pituitary hyperplasia, enhances local AT2 expression (measured by Western blot and RT-PCR) concomitantly with downregulation of ANG II type 1 (AT1) receptors. In vivo progesterone treatment of estrogen-induced pituitary hyperplasia did not modify either the ANG II receptor subtype expression pattern or octapeptide-induced and AT1-mediated calcium signaling. Nevertheless, an unexpected potentiation of the ANG II prolactin-releasing effect was observed in this group, and this response was sensitive to both AT1 and AT2 receptor antagonists. These data are the first to document that ANG II can act at the pituitary level through the AT2 receptor subtype and that estrogens display a differential regulation of AT1 and AT2 receptors at this level.

prolactin; calcium signaling; Western blot; reverse transcriptase-polymerase chain reaction



Address for reprint requests and other correspondence: D. Becu-Villalobos, Instituto de Biología y Medicina Experimental-CONICET, Vuelta de Obligado 2490, 1428 Buenos Aires, Argentina (E-mail: dbecu{at}dna.uba.ar).




This article has been cited by other articles:


Home page
Reproductive SciencesHome page
Kai Chen, D. C. Merrill, and J. C. Rose
The Importance of Angiotensin II Subtype Receptors for Blood Pressure Control During Mouse Pregnancy
Reproductive Sciences, October 1, 2007; 14(7): 694 - 704.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.